



Coordination group
of leading cancer
organisations

ACCELERATE
THE PROGRESS
AGAINST CANCER
WORLDWIDE

Webinar PATHWAYS TO PRECISION CANCER PREVENTION March 20th, 2025

Register here : [LINK](#)



MODERATOR



Dr David Crosby – Head of Prevention & Early Detection Research CRUK

David Crosby is the Head of Prevention and Early Detection Research at Cancer Research UK. With a background in pharmacology and a PhD in cell signaling, he transitioned from academia to industry, working with Linde Gas Therapeutics, and later joined the UK's Medical Research Council. At CRUK, he develops strategies to advance cancer prevention and early detection through multidisciplinary research.



What does a world look like in 50 years, when the majority of cancers are prevented?



What are the **emerging hot areas** and **great hopes** for cancer prevention?



What are the **gaps and barriers** in the current research landscape? What is stopping us and why hasn't precision prevention happened already?



What are the **incentives, next steps** in the journey?
How can healthcare systems prepare?

Coordination group
of leading cancer
organisations



ACCELERATE
THE PROGRESS
AGAINST CANCER
WORLDWIDE

Webinar PATHWAYS TO PRECISION CANCER PREVENTION March 20th, 2025

Register here : [LINK](#)



SPEAKERS



Prof. Dr. Matthias Kloor - Senior scientist, Department of Applied Tumor Biology, University Hospital Heidelberg

Dr. Matthias Kloor is acting Director of the Department of Applied Tumor Biology at Heidelberg University Hospital. His main expertise is tumor biology and cancer immune prevention. He leads the Heidelberg University site of the NCI-funded CAP-IT U54 project, focusing on next-generation cancer immunoprevention. He spearheaded the first clinical trial of a frameshift peptide vaccine for MSI cancer patients and is Project Leader of the INDICATE Network, examining the role of HLA genotype in Lynch syndrome.



Dr. Susan M. Domchek – Oncologist at the University of Pennsylvania, Executive Director of the Basser Center for BRCA and Professor in Oncology at the Perelman School of Medicine

Dr. Susan M. Domchek is an oncologist at the University of Pennsylvania where she is Executive Director of the Basser Center for BRCA. Her research aims to develop new strategies for treatment, risk reduction, and cancer interception for those with a genetic susceptibility for cancer. An elected member of the National Academy of Medicine, she has more than 450 scientific publications.



Dr. Hormuzd A. Katki – Senior Investigator in the Biostatistics Branch in the NCI

Dr. Hormuzd Katki is a tenured senior investigator in the biostatistics branch of the US national cancer institute. Dr. Katki's research focuses on cancer screening and prevention and particularly interested in developing individualized prediction-based approaches to cancer screening. He developed risk models for cervical cancer screening that underlie US cervical screening and management guidelines. He has also developed prediction models for use in lung cancer screening that are used in the clinic.



Dr. Andrew R. Reynolds - Senior Director Scientist, AstraZeneca

Dr Andrew Reynolds is a scientist based in AstraZeneca's R&D centre in Cambridge, UK. Andrew completed his PhD at the Cancer Research UK London Research Institute in 2002, followed by a Post-doc at Barts Cancer Institute (BCI) from 2002 to 2007. He was then a Group Leader at the Institute of Cancer Research (ICR) in London from 2007 to 2016, before then joining AstraZeneca in 2016. His research at AstraZeneca is focused on premalignant disease and the potential to develop medicines for cancer prevention.